Oral Dexpramipexole

Market Landscape

Unmet Needs Persist for Patients with Asthma and Other Eosinophilic Diseases

Scroll to discover
Market Landscape

What is the Burden of Asthma?

Knopp Biosciences Physicians

Currently, Most Eosinophil-Lowering Drugs for Asthma Are Monoclonal Antibodies that Must Be Injected or Infused in Regular Clinic Visits.

Knopp is Advancing Dexpramipexole, an Eosinophil-Lowering Oral Agent for Asthma

Find Out More About Dexpramipexole

Hypereosinophilic Syndrome

For some, eosinophils migrate into specific tissues, damaging organs through the release of toxic proteins and signaling molecules

The heart is frequently affected in HES, leading to ventricular damage and eventual cardiac failure

Other targets include the skin, nervous system, lungs, GI tract, liver, spleen and eyes

Currently, the standard of care for those with HES is corticosteroids, which may present significant side effects

Side effects of steroids may include hormone suppression, elevated blood sugar, loss of bone density, mood and behavioral disturbances.

1/3 of HES patients fail to respond to steroid administration.

Woman Treating Patient for Asthma

Dexpramipexole is under investigation as a potential solution for those suffering with hypereosinophilic syndrome